This content was originally published by DeepIntent.  Healthcare marketing is undergoing a transformation, with data-driven insights now serving as the foundation for how brands connect with consumers and providers. That’s why DeepIntent is excited to spotlight PurpleLab®, a data partner that’s helping pharmaceutical brands and agencies connect with their audiences in more effective and meaningful…

Biomarker testing can drastically extend survival across multiple cancer types. But gaps in adoption persist. Are payers, pharma and policymakers doing enough to ensure these tests actually having an impact in the real world? PurpleLab recently conducted a study, Maximizing Survival: The Real-World Impact of Biomarker Testing in Metastatic NSCLC, to shed light on how…

As the healthcare industry continues to face data challenges, PurpleLab® is making significant investments in its data and infrastructure to reinforce its position as a trusted leader in real-world data (RWD). We’ve recently secured several new data sources that will dramatically improve the comprehensiveness and composition of our data.(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Although randomized controlled trials remain a cornerstone of evidence generation, pharmaceutical and biotech companies are increasingly recognizing the necessity of leveraging real-world data
(RWD) and real-world evidence (RWE) earlier in the product lifecycle to inform decision-making.

Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

Change is the only constant in digital advertising—and the upcoming retirement of Microsoft’s Xandr DSP is a perfect example of this volatility. For many pharma marketers and agencies, this shift isn’t just another platform update; it’s a critical juncture that could reshape how you reach your audiences and drive ROI. So, what happens when a…

The US spends twice as much on health per person as other high-income nations. Health expenditures per person reached $13,432 in 2023, which was over $3,700 more than any other peer nation.  According to the Commonwealth Fund, “reductions in administrative burdens and drug costs could substantially reduce the difference between U.S. and peer nation health…

Starting January 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is rolling out a major new payment model called the Transforming Episode Accountability Model, or TEAM. This program will change how hospitals get paid for certain surgeries – and it’s something hospitals need to start preparing for now. Understanding what it is, who…